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Summary
The soluble granule chymase, rat mast cell protease-II (RMCP-1I), is abundantly expressed in
intestinal mucosal mast cells (MMC) but its function is not known. One hypothesis is that
RMCP-Il degrades the epithelial basement membrane and promotes the loss of enterocytes
typically associated with type I hypersensitivity reactions in the rat. To test this hypothesis more
directly, ex vivo perfusion of the cranial mesenteric artery and jejunal lumen was used to mon-
itor the anaphylactic release of RMCP-11 and its effects on mucosal permeability and epithelial
integrity. Within 2 min of intravascular challenge with soluble adult Nippostrongylus brasiliensis
worm antigen there was a 1,000-fold (P <0.02) increase in the concentration of RMCP-11 in
the vascular perfusate from the jejunum of Nippostrongylus-sensitized rats but not the controls.
Similarly, translocation of RMCP-1I into the gut lumen increased 10-fold (P <0 .02) after 2
min only in worm antigen-challenged immune rats. Using an identical protocol, but incorpo-
rating Evans blue-labeled human serum albumin (EB-HSA) in the vascular perfusate, the tim-
ing of the release ofRMCP-II into the two compartments was very similar to the first experi-
ment and furthermore the translocation ofEB-HSA increased 18-fold (P <0.05) after 4 min in
sensitized rats challenged with worm antigen. To examine the effects of RMCP-11 more di-
rectly 1 mg ofthe highly purified chymase was introduced into the cranial mesenteric artery in
ex vivo perfused normal rats. A significant (P <0.05) 70-fold increase in concentration of
RMCP-II in jejunal perfusate occurred after 6 min. In a repeat dose-response experiment, in-
fusion of 0.375, 0.75, or 1 .5 mg of RMCP-11, together with EB-HSA, established that the cu-
mulative amounts of RMCP-II and EB-HSA translocated from the vasculature to the gut lu-
men in each perfusion (during the 10-min period of RMCP-II infusion) were significantly
correlated. Analysis of intestinal perfusates by SIDS-PAGE and by Western blotting using mono-
clonal anti-RMCP-11 antibody confirmed that there was a concomitant translocation of both
the protease and EB-HSA into the gut lumen. Histological evaluation of the mucosa failed to
reveal any significant morphological change in any of the experiments. The rapid development
ofmacromolecular leak, its association with the translocation of RMCP-11, and the absence of
gross epithelial lesions, suggest for the first time that a mast cell granule chymase increases epi-
thelial permeability via a paracellular route and implies that the substrate may be a protein, or
proteins, in the epithelialjunctional complex.
Hypersensitivity reactions in the gastrointestinal tract
are associated with a secretory response ofthe epithe-
lium and, frequently, increased permeability to macromol-
'Abbreviations used in this paper: cx,Pl, al -protease inhibitor; EB-HSA, hu-
man serum albumin labeled with Evans blue dye; MMC, mucosal mast
cells; RMCP-11, rat mast cell protease-11; we, worm equivalents.
ecules (1, 2). Mast cell activation has been implicated as a
cause of these changes by a variety of experimental ap-
proaches including direct observation of mast cell degranu-
lation supported by measurement of the systemic release of
the soluble chymase rat mast cell protease-II (PMCP-1I)'
(3, 4); measurement ofjejunal ion transport in rats (5) and
mice (6) where the density of mast cells in the mucosa var-
ies; use of mast cell stabilizing agents to block the release of
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of these experiments suggest a role for mast cells in the
modulation ofmucosal function, the relative importance in
vivo of specific mediators has not been clearly established .
Of the mediators released by mast cells histamine, adeno-
sine, platelet-activating factor, prostaglandins, leukotrienes
and some cytokines have all been shown to alter mucosal
function in experimental models (2, 8-16) . However, in-
vestigation of the interactions between epithelia and the
mast cell granule serine proteases tryptase and chymase,
which make up a substantial percentage of the total granule
protein (17) content, has largely been neglected.
The intestinal mucosa of the rat contains many mast cells
which are the majorsource ofthe granule chymaseRMCP-
11 . After infection with the intestinal nematode Nippos-
trongylus brasiliensis there is hyperplasia o£intestinal mucosal
mast cells (MMC) and the concentration ofRMCP-11 may
increase up to 10-fold to reach 2-3 mg RMCP-11/g wet
wt ofintestine (18) . Since RMCP-11 containingMMC are
confined to the mucosa (19) the concentration of this pro-
tease stored in the lamina propria can be conservatively es-
timated to be 4-6 mg/g wet wt. When Nippostrongylus-
sensitized rats are challenged intravenously with solubleN .
brasiliensis antigen systemic levels ofRMCP-11 reach 400-
800 kg/ml serum (3, 20) . This represents 4-8 mg RMCP-
11 in the systemic circulation o£ a 250-300-g rat. Similarly,
1-2mg ofRMCP-11 can be recovered from the lumen of
the intestine within 5 min of challenge (20) . The massive
release of RMCP-11 during anaphylaxis is associated with
severe damage to the intestinal mucosa and extensive epi-
thelial shedding (3) . While these lesions may potentially be
a consequence of anoxic damage it has been suggested that
proteolysis ofbasement membrane proteins by RMCP-11 is
causally involved (4, 20) . However, neither the native sub-
strate ofRMCP-11, nor the extent to which proteolysis is
inhibited by native serpins has been defined, and it is there-
fore unclear whether RMCP-11 plays a significant role .
To examine the relationship between mucosal perme-
ability and the enteric release ofRMCP-11 in more detail,
an ex vivo perfusion model was established . This model in-
volves simultaneous perfusion ofthe vasculature andlumen
of the jejunum in situ, allowing comparison of the precise
timing of mast cell mediator release into both compart-
ments . Removal of circulating cells and plasma proteins by
perfusion also makes it possible to examine the effect of di-
rect infusion of proteases in the absence of native inhibi-
tors . Using this model we examined the effect on jejunal
mucosal permeability o£ both systemic challenge of sensi-
tized rats with worm antigen and direct infusion ofRMCP-11 .
Our results suggest that RMCP-11 is directly implicated in





Male Wistar rats (290 ± 5 g ; Bantam and Kingman,
Hull, UK) were used for all experimental protocols . Immune rats
were infected twice with 3,000 Nippostrongylus brasiliensis third-
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stage larvae by subcutaneous injection (21), 4 and 1 wk before
perfusion experiments . Naive control rats were not exposed to
the parasite . Soluble worm antigen was prepared from whole
adultN . brasiliensis worms as previously described (22) . The chal-
lenge dose of 100 worm equivalents (we) ofworm antigen (total
protein concentration of 1 .1 mg/ml) was administered into the
vascular perfusate as a bolus in 0.1 ml ofKrebs-Ringer buffer .
Ex Vivo Perfusion .
￿
The model ofjejunal perfusion has been
described previously (23) . Briefly, under general anesthesia (intra-
peritoneal pentobarbitone sodium 84 mg/kg) the vasculature of a
30.8 ± 0.6-cm section ofjejunum (starting 5 cm distal to the lig-
ament ofTreitz) was isolated, with the intestine remaining in situ,
and was then perfused via the cranial mesenteric artery at a rate of
1.5 ml/min with Krebs-Ringer buffer, pH 7.4, gassed with 95%,
OZ/5%COZ , containing 5mM glucose and 10% wt/vol Ficoll 70
(Sigma Chemical Co ., Poole, UK) . In some experiments (de-
tailed in Results) human serum albumin (10 mg/ml) (Sigma
Chemical Co .) labeled with Evans blue (EB-HSA) (Sigma
Chemical Co .) was included in the vascular perfusate . The vascu-
lar perfusate effluent was collected via a cannula inserted in the
hepatic portal vein . Thelumen ofthe isolated section ofjejunum
was perfused simultaneously with Krebs-Ringer buffer gassed
with 95%OZ/5%COZ containing 5mM glucose at a rate of 1.8
ml/min. Once perfusion was established, the rat was killed with
an overdose of pentobarbitone sodium .
The vasculature of the isolated tissue was continuously per-
fused and antigen was introduced via a "Ypiece" over a 10-s pe-
riod starting at 21 min 50 s after the start ofperfusion . Infusion of
purified RMCP-11 was carried out using a syringe infusion pump
(Harvard Apparatus Ltd., Edenbridge, UK) over a 10-min period
starting at 22 min after the start ofperfusion . Samples were col-
lected for 1 min in every 2 min from the vascular and lumenal
outflow during the 20-min basal perfusion period and then con-
tinuously at 30-s (vascular) and 1-min (gut lumen) intervals after
antigen challenge and 2-min intervals (vascular and gut lumen)
after the start o£ infusion ofRMCP-11 . At the end of the perfu-
sion period the section of jejunum perfused was measured
(weight and length) and samples were immediately fixed or fro-
zen for histological examination and assay ofRMCP-11 .
Purification ofRMCP-II.
￿
RMCP-11 was isolated from the small
intestine of rats infected withN . brasiliensis using the method pre-
viously reported (24) . The stock solution ofRMCP-1I was finally
concentrated and purified by elution from a Mono-S (Pharmacia,
Milton Keynes, UK) ion exchange column in 10 mM sodium
phosphate, 120mM NaCl . The protease used for infusion exper-
iments was >90% pure as determined by SDS-PAGE (Fig. 1) and
was 96% active when titrated against equine al -protease inhibitor
ofknown concentration (25) .




of RMCP-II purified from rat
small intestine . Proteins sepa-
rated by 12% PAGE using the
Laemmli technique and stained
with Coomassie blue . Lane 1,
mol wt standards ; lane 2,
RMCP-II .Measurement of RMCP-II by ELISA .
￿
The concentrations of
RMCP-11 were measured in vascular and lumenal perfusates and
in tissue, by ELISA as previously described using a mouse mAb to
capture and a horseradish peroxidase-conjugated sheep poly-
clonal antibody (26). 3,3',5,5'-tetramethylbenzidine was used as a
substrate (Kirkegaard and Perry Laboratories Inc., Gaithersburg,
MD). The lower quantifiable limit of detection of the assay was
0.25 ng/ml. 2-3-cm weighed segments ofjejunum, frozen after
each perfusion, were homogenized on ice in 20 mM Tris/HCI
pH 7.5; 1 M NaCl, centrifuged at 8,000 g for 30 min, and the su-
pernatant analyzed by ELISA for RMCP-11 content which was
then expressed in micrograms per gram wet weight ofintestine.
Measurement of Albumin in Luminal Perfusates.
￿
In experiments
investigating the change in permeability to albumin the vascular
perfusate was prepared containing EB-HSA. Precipitation of the
vascular perfusate before experiment (and samples of gut lumen
perfusate after experiment) with 10% TCA demonstrated that all
of the dye was protein bound. The amount of EB-HSA present
in the luminal perfusates was assessed as a marker of combined
endothelial and epithelial macromolecular permeability. A spec-
trophotometer (DU-650; Beckman Instruments, Inc., Fullerton,
CA) was used to measure the optical density of the gut lumen
samples and standards at 620 nm. Standard curves were prepared
by dilution of preexperiment vascular perfusate with Krebs buffer
and the lower limit of detection of the assay was equivalent to 5
Rg/ml of albumin. The human serum albumin had no detectable
serine proteinase inhibitor contamination.
Histology.
￿
Samples ofjejunum were opened longitudinally af-
ter perfusion and wrapped around the barrel of a plastic pipette
with the luminal surface outward. They were immediately fixed
in 4% paraformaldehyde in PBS, stored in 70% ethanol, and sub-
sequently embedded in paraffin wax. 4-prn longitudinal sections
(27) were cut, rehydrated, and stained with hematoxylin and
eosin. Mucosal morphology was assessed in relation to previously
described mucosal lesions (28, 29) . At least 50 villus/crypt U (27)
were examined per section and lesions were scored on a scale 0-5
where 0 = no lesions and 5 = more than 50% of the villi af-
fected. Changes noted and scored were loss of enterocytes from




Statistical analyses were performed using
Minitab software (Minitab Inc., University Park, PA) . Flow rate
time course data (presented as mean ± SEM) was analyzed using
one-way analysis ofvariance and the Student's t test where appro-
priate to examine differences occurring with time within groups
and differences between treatment groups for given time points.
RMCP-11 and albumin concentration data (presented graphically
as median and range) in vascular and luminal perfusates were ana-
lyzed in a similar way using the nonparametric tests, Kruskal-
Wallis and Mann-Whitney, as appropriate. Tissue concentrations
ofRMCP-11 were also compared using the nonparametric tests.
Within the text, overall mean values for RMCP-11 concentra-
tions for pre- and postchallenge time periods are quoted for ease
ofcomparison but all probability values refer to statistical analyses
as defined above.
Correlations between albumin and RMCP-11 translocation
into the gut lumen were investigated using linear regression. Re-
sults were considered to be statistically significant if a probability
value of P -0.05 was obtained using any ofthe tests specified.
Results
The Effects of Mast Cell Activation after Intravascular Chal-
lenge with Worm Antigen.
￿




cally mediated release of RMCP-11 from MMC and to
compare the intravascular accumulation of the protease
with its translocation into the gut lumen, ex vivo perfu-
sions of the jejunum were performed in three groups of
rats. Naive rats (n = 5) were perfused and after 21 min 50 s
challenged with 100 we of soluble N. brasiliensis antigen via
the cranial mesenteric artery. Two groups of rats immune
to N. brasiliensis were also perfused and after 21 min 50 s
rats in one group (n = 5) were challenged with 100 we of
worm antigen over a 10-s period and, in the other, with
BSA (n = 5) . The following parameters were then mea-
sured: output ofthe vascular perfusate from the portal vein;
concentrations of RMCP-11 in the vascular perfusate be-
fore (first 20 min) and after (the following 10 min) intravas-
cular challenge with antigen; concentrations of RMCP-II
in the perfusate from the jejunal lumen before and after
challenge.
The outflow rate ofthe vascular perfusate remained con-
stant for the first 20 min of perfusion for all treatment
groups (Fig. 2 A) . Within 60-120 s after challenge with
worm antigen the outflow rate decreased significantly (P <
0.001) in immune rats, but not in naive controls or im-
mune rats challenged with BSA, when compared to the
basal level. From this time point until the end of the exper-
iment the vascular flow rate was significantly less (P <
0 .05) in the immune challenge group compared to the
other two groups except at 26 and 29 min after the start of
perfusion. This result suggests either that there is an immu-
nologically initiated alteration in vascular tone or increased
endothelial permeability with subsequent movement of
fluid into the tissue within 2 min of specific antigen chal-
lenge.
During the initial 20 min of perfusion, baseline secretion
of RMCP-II into the vasculature was constant in all groups
(Fig. 2 B) . However, the concentration ofRMCP-11 mea-
sured in the vascular perfusate outflow was significantly
greater in the two groups of immune rats (mean values for
20-min period were: immune challenge 18.5 ng/ml; im-
mune control 11 .4 ng/ml) when compared to the naive
controls (3.9 ng/ml) (P <0.05) . Within 30 s of injecting
the bolus of worm antigen the RMCP-11 in the vascular
perfusate of immune rats increased from -10 ng RMCP-
II/ml to ^100 ng/ml (P <0.02) and after a further 60 s to
10,000 ng/ml (Fig. 2 B) . The concentrations of RMCP-11
in the vascular perfusate from the naive controls given
worm antigen and the immune controls challenged with
BSA were unaltered, although the concentration ofRMCP-II
(7.5 ng/ml) in the perfizsate from immune controls was sig-
nificantly (P <0.05) higher than from the naive controls
(3.2 ng RMCP-II/ml).
Baseline secretion of RMCP-11 into the gut lumen re-
mained constant during the initial period of perfusion and,
in parallel with the secretion into the vasculature, was sig-
nificantly greater (P <0 .02) in both immune challenge
(41 .9 ng/ml) and immune control (28.8 ng/ml) groups
than the naive controls (0.74 ng/ml) (Fig. 2 C . After chal-
lenge there was no significant change in the output of
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The effects of mast cell activation in ex vivo perfused je-
junumafter intravascular challenge (1) with worm antigen (naive O and
immune E rats) or BSA (immune/control *). (A) Outflow rate (mean _'
SEM) of vascular perfusate from the hepatic portal vein. Concentration
(median and range) ofRMCP-II measured by ELISA in (B) vascular per-
fusate outflow and (C) perfusate outflow from the lumen ofthe jejunum.
tion remaining at 13 .1 ng/ml in the immune controls and
1 .0 ng/ml in the naive rats (P <0.02) . 60 s after challenge
of immune rats with worm antigen the concentration o£
RMCP-II in the the jejunal lumen was noticeably higher
(70.1 ng/ml) than baseline, further increasing to 148 ng/ml
in the next 60 s at which point it was significantly greater
than baseline values (P <0.02) suggesting that the jejunal
mucosa had become more permeable. From this time point
until the end ofthe experiment significantly more RMCP-
II could also be detected in samples from the immune chal-
lenged rats compared to the immune controls (P <0.02)
(Fig. 2 C) .
There was no difference in the concentration ofRMCP-II
in the tissue homogenates from immune or immune con-
trol animals (median values 579 vs 553 ia,g/g perfused tis-
sue), but there were significantly lower levels in tissue from
the naive control rats (59 N.g/g perfused tissue, P < 0.01) .
The Effects ofMast Cell Activation on Mucosal Permeability to
Macromolecules. A further experiment was performed to
assess whether the apparent increase in permeability of the
jejunal epithelium to RMCP-II after challenge of primed
rats with worm antigen represented a generalized increase
in macromolecular permeability. The experimental proto-
col was similar to that reported above using three groups of
rats, naive (n = 5), immune challenge (n = 4), and im-
mune control (n = 3) . In contrast to the first experiment
EB-HSA was included in the vascular perfusate throughout
the perfusion so that alterations in the leak of protein into
the jejunal lumen could be monitored. Measurements were
made ofthe perfusate output from the portal vein and concen-
trations ofRMCP-II in the vascular and lumenal perfusates.
As in the first experiment vascular outflow rate from the
portal vein was constant for all treatment groups for the first
20 min of perfusion. After challenge of immune rats with
worm antigen the outflow rate was reduced compared to
baseline (P <0.001), but no change was observed in the
flow rate from naive or immune rats challenged with BSA
(data not shown). Therefore, after challenge, the flow rate
was significantly less in the immune challenge group com-
pared to the other two groups (P --0.05).
RMCP-II release into the vasculature followed a pattern
similar to that discussed above, with baseline RMCP-II
concentrations being significantly higher in immune ani-
mals (immune challenge 15.9 ng/ml, immune control 19.4
ng/ml) when compared to naive controls (1 .5 ng/ml) be-
fore challenge (P <0.05) (Fig. 3 A) . The increase above
baseline levels in protease concentration after challenge of
the immune group with worm antigen also followed a sim-
ilar pattern to the first experiment reaching statistical signif-
icance (P <0.03) (^6,000 ng/ml) within 30 s after chal-
lenge and increasing to a maximum after 60 s (10,000 ng/
ml). The concentration of RMCP-II in the vascular perfu-
sate of the two control groups did not alter significantly af-
ter challenge, remaining at 1.4 ng/ml in naive animals and
18 .4 ng/ml in the immune control group.
The secretion of RMCP-II into the gut lumen also fol-
lowed a pattern similar to that seen before with greater
concentrations in the gut lumen of immune animals (im-



















The effect ofmast cell activation on the permeability of the
mucosa ofex vivo perfusedjejunum to macromolecules. The concentra-
tion of RMCP-II (median and range) measured by ELISAin (A) vascular
perfusate and (B) luminal perfusate before and after challenge with worm
antigen (naive O and immune " rats) or BSA (immune/control *) . (C)
Corresponding concentration (median and range) of EB-HSA (optical
density measured by spectrophotometer at 620 nm) in luminal perfusate.




mune challenge 44 .8 ng/ml, immune control 31 ng/ml)
compared to naive (0.3 ng/ml) before challenge (P <0.04) .
After challenge of immune rats a trend to increased
RMCP-II concentrations above baseline was observed at
60 s (115.7 ng/ml) ; however, the increase did not achieve
significance (P <0 .03) until 240 s after challenge (4,600
ng/ml) (Fig. 3 B).
In the prechallenge period there were very low levels of
translocation of albumin from the vasculature to the gut lu-
men (Fig. 3 Q in all three treatment groups (immune chal-
lenge 5.0 lx,g/ml, immune control and naive <5.0 N,g/ml).
However from 180 s after challenge of immune rats with
worm antigen there was a clear trend to increased concen-
trations of labeled albumin (45.2 N,g/ml) in the gut lumen
when compared to both baseline measurements and to the
other groups at each time point. The increase (to 90.3 jig/
ml) reached statistical significance (P <0.05) when com-
pared to baseline at 240 s. These results show that there is
minimal protein leak across the jejunal mucosa in this
model before challenge with worm antigen but that after
challenge ofimmune rats with worm antigen there is an in-
crease in permeability to both RMCP-II and albumin.
The spectrophometric assay used routinely for analysis of
EB-HSA was 1,000-fold less sensitive than the ELISA used
for RMCP-II measurement. Therefore SDS-PAGE and
Western blotting were used to see if a closer correlation be-
tween the onset of increased RMCP-II and albumin trans-
location into the gut lumen could be identified. Albumin
was detected by Coomassie blue staining and RMCP-II by
both Coomassie staining ofgels and Western blotting with
a specific mAb against RMCP-II. Increased concentrations
ofEB-HSA and of RMCP-II were both detected by 120 s
after challenge. (A representative gel and blot from an im-
mune rat challenged with worm antigen are shown in Fig.
4, A and B.)
Furthermore, regression analysis ofthe cumulative amounts
ofRMCP-II and Evans blue-labeled albumin (Fig. 5) leak-
ing into the gut lumen of immune rats at each time point
revealed a strong correlation (r = 0.97) . Both of these re-
sults suggest that the translocation of the two macromole-
cules was related and probably occurred by the same route.
In agreement with the results of the first experiment no
difference in tissue content of RMCP-II was observed be-
tween the immune challenge and immune control rats
(median value 681 .2 vs 631 .9 Wg/g perfused tissue) but
there was significantly less RMCP-II in naive rat tissue
(65 .3 l.Lg/g perfused tissue, P <0.03) .
The Effects ofDirect Infusion of RMCP-II into the Vascula-
ture of Ex Vivo Perfused Jejunum. The previous experi-
ments had revealed changes in epithelial permeability re-
lated to mast cell activation and also shown a correlation
between the translocation of RMCP-II and albumin into
the jejunal lumen. In a further series of experiments we
aimed to demonstrate whether the protease itself could be
responsible for the observed alterations in epithelial perme-
ability by infusing RMCP-II into the vasculature of ex
vivo perfused jejunum.
In the first experiment a total of 1 mg of purifiedFigure 4.
￿
SDS-PAGE and Western blot analysis of timing ofchanges
in permeability to macromolecules in ex vivo perfused jejunum from an
immune rat challenged with worm antigen . Duplicate samples of human
serum albumin (HSA), RMCP-11, and jejunal lumen perfusates taken at
different times during the perfusion were separated by 12% SDS-PAGE
and then one gel was blotted on to nitrocellulose . The first gel (A) stained
with Coomassie blue demonstrated increased levels of albumin in the In-
men ofthe jejunum after challenge with worm antigen . (B) Western blot
from the second gel showing RMCP-11 detected with a mouse mAb
against RMCP-11 and peroxidase-labeled conjugate and diaminobenzi-
dine . Note that the first detectable appearance ofRMCP-11 by Western
blot, at 24 min, is associated with an increased intensity of staining for
HSA in the Coomassie-stained gel . Translocated RMCP-11 is visible on
the Coomassie-stained gel at 24 min and is readily detected at this time
point by Western blotting. Arrow (1) indicates time of challenge with
soluble N . brasiliensis antigen .
RMCP-11 (66.66 N ,g/ml vascular perfusate) was infused
into the vasculature of each of four naive rats over a 10-
min period beginning 22 min after the start of perfusion .
The perfusion was then continued for a further 10 min .
Measurements were recorded of the vascular perfusate out-
flow rate and concentrations ofRMCP-II in the jejunal In-
men perfusate . Infusion ofRMCP-11 had no effect on the
flow rate of the vascular perfusate (data not shown) . As
noted in all previous experiments the basal secretion of en-
dogenous RMCP-II in naive rats during the first 20 min of
perfusion was very low (0.8 ng/ml) (Fig . 6) . Rising con-
centrations ofRMCP-II (12.5 ng/ml) could be measured
in the gut lumen from 4 min after the start of infusion and




Regression analysis of the relationship between concentra-
tion of albumin and RMCP-11 translocated into luminal perfusate after
challenge of immune rats with worm antigen . Each point represents the
cumulative amount ofprotein for an individual animal at 1 (O), 2 (" ), 3
(O), 4 ("), 5 (0), 6 ("), 7 (O), 8 ("), 9 (*), 10 (*) min after challenge;
rz = 0.90, P <0.001 . log y = 0.76 logx - 0.84 .
ng/ml) . Therefore in the absence of other mast cell media-
tors it appeared that RMCP-11 could cross both endothelial
and epithelial barriers but it was not certain from this ex-
periment that a change in permeability had occurred . Thus,
in a further trial, EB-HSA was included in the vascular per-
fusate throughout the perfusion period .
In the second experiment 0.375, 0.75, or 1 .5 mg of
RMCP-11 (25, 50, and 100 N ,g/ml of vascular perfusate)
were infused over a period of 10 min into the perfused
mesenteric arteries ofthree groups of two naive rats . There
was, again, no change in the flow rate of the vascular perfu-
sate during the perfusion . Before infusion of RMCP-1I,
concentrations of albumin and endogenous RMCP-11 in
the perfusate from the jejunal lumen were both very low
(albumin 7.6 N ,g/ml, RMCP-11 0.25 ng/ml) (mean values
are presented in Fig. 7,A and B) . In all rats, the concentra-
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Direct infusion of l mg ofpurified RMCP-11 into the vascu-
lature of the ex vivo perfused jejunum of naive rats . Concentration of
RMCP-11 (median + range) increases significantly (P <0.05) in the per-
fusate from the lumen of the jejunum when compared to the baseline by








* 100 jig/ml (n-2)
0 50 pg/ml (n=2)










The effect ofinfusion of25, 50, and 100 N,g/ml of RMCP-11
on macromoleculer permeability of ex vivo perfused jejunum ofnaive rats.
Mean concentrations of (A) RMCP-II and (B) albumin in the luminal
perfusate before, during, and after infusion of three doses of RMCP-II .
tion of RMCP-II increased in the jejunal perfusate al-
though the timing of this increase varied in individuals
from 1 to 6 min after onset of infusion . Leakage of EB-
HSA into the gut lumen also started after infusion of
RMCP-II but appeared to be delayed relative to the leak of
RMCP-II (Fig . 7, A and B) . As was discussed above, the
detection method for EB-HSA was 1,000-fold less sensitive
than the ELISA for RMCP-II and luminal perfusates were
further investigated by SDS-PAGE and Western blotting .
An example in which 1 .5 mg ofRMCP-II was infused at
100 Rg/ml starting at 22 min shows that albumin and im-
munoreactive RMCP-II could both first be detected at 24
min (Fig. 8, A and B) . The concentrations of albumin and
RMCP-II increased over the period of infusion and both
were readily detected by SDS-PAGE at 26 min (Fig. 8 A) .
Interestingly, RMCP-11 reactivity on the blot shows a
higher mol wt (70-kD) band suggestive of a serpin/pro-
tease complex . At subsequent time points, free RMCP-II
1877
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Figure 8 .
￿
SDS-PAGE and Western blot analysis of changes in perme-
ability to macromolecules in ex vivo perfused jejunum from a naive rat
before and during infusion ofRMCP-II (100 p,g/ml) . Duplicate samples
ofjejunal lumen perfusates taken at different times during the perfusion
were separated by 12% SDS-PAGE and proteins from one gel were
Western blotted on to nitrocellulose . (A) Gel stained with Coomassie
blue demonstrating increased levels of albumin in lumen 2 min after the
start of protease infusion. (B) Western blot of duplicate samples stained as
previously described showing appearance of immunoreactive RMCP-II
in lumen, first detected as a high mol wt (70-kD) complex 2 min after the
start of infusion . Note the presence of a second lower mol wt (59-kD)
RMCP-II immunoreactive band at 26-30 min . Arrow (1) indicates start
ofRMCP-II infusion.
was visible by SDS-PAGE and was strongly stained on
Western blot (Fig . 8 B), weak staining of an additional im-
munoreactive band of 59 kD was visible from 26 to 30
min . This result confirms the spectrophotometric andELISA
results . Furthermore when the ELISA and EB-HSA data
were corrected for the length of gut perfused, a significant
correlation between the total cumulative amounts of
RMCP-II and EB-HSA translocated into the gut lumen of
each rat during the 10-min period of infusion could be
shown (r = 0.98, P 60.0001) (Fig . 9) .
Histology . There was no gross evidence of mucosal
damage in any of the experiments described above . A few
minor lesions, including some loss of epithelium from the
villus tips or separation of epithelium from the lamina pro-
pria, were detected histologically in several of the samples.
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Figure 9. Correlation between the total cumulative RMCP-11 and
EB-HSA (corrected for length of gut perfused) translocated into the gut
lumen of individual rats during the 10-min period of RMCP-11 infusion.
(y = 84.8x - 154.5; r = 0.98; P 60.0001).
separation from the villi to suggest that immunological re-
lease of RMCP-II was associated with significant epithelial
damage (Table 1) .
Direct infusion of RMCP-II at concentrations in excess
of those observed in ex vivo challenged rats but at levels
seen in sera of rats in vivo 5-15 min after the induction of
anaphylaxis (20) also failed to produce significant changes
in mucosal histology (Table 1 and Fig. 10).
Discussion
The functional significance of the translocation of the
mast cell granule chymases into the gut lumen during intes-
tinal hypersensitivity reactions is not known. Therefore,
the present experiments, using ex vivo perfused rat je-
junum, were designed to address the following questions:
(a) what is the temporal relationship between the intravas-
cular and transmucosal release of the MMC granule chy-
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mase RMCP-II? and (b) is the translocation of RMCP-II
into the gut lumen associated with increased permeability
to other macromolecules and histologically detectable mu-
cosal damage? In addition, does infusion of RMCP-II di-
rectly into the cranial mesenteric artery alter mucosal per-
meability or cause histological damage? Answers to these
questions would provide an insight into the function ofthe
soluble granule chymases and the role of mast cells at mu-
cosal surfaces.
Ex vivo perfusion removes the plasma proteins and
formed elements ofthe blood so that some of the potential
effectors of systemic shock such as IgG and complement,
and erythrocytes, which aggregate within the postcapillary
venules ofthe gut, are absent or greatly reduced in concen-
tration. Nevertheless, intravascular challenge of sensitized
rats with soluble worm antigen resulted in a significant re-
lease of RMCP-II into the vascular perfusate within 30 s
(Figs. 2 and 3) with maximum values of 6-10 p,g/ml I min
later. The rapid passage of this 30-kD macromolecule
across the endothelium is most likely mediated by hista-
mine or platelet-activating factor released from activated
mast cells (30) . By contrast, translocation ofRMCP-II into
the jejunal lumen was delayed for at least a further 30-60 s.
The dissociation between the vascular and epithelial events
suggest that distinct mechanisms may be operating in each
compartment or that it reflects the difference in diffusion
path lengths. When EB-HSA was added to the vascular
perfusate, concentrations of RMCP-II and EB-HSA in the
intestinal perfusate displayed a highly significant positive
correlation; indicating that EB-HSA leak could be contin-
gent on permeability changes brought about by the pro-
teolytic activity ofRMCP-II. Analysis of the intestinal per-
fusates by SDS-PAGE and Western blotting confirmed the
ELISA and Evan's blue data, showing that both macromol-
ecules are translocated concomitantly. The relationship be-
tween RMCP-II and mucosal permeability to macromole-
cules was investigated futher by infusing purified RMCP-II
into the vasculature. In both series of experiments, the in-
fusion of RMCP-II into normal jejunum resulted in the
0, no lesion; 5, extensive lesions. No significant differences were noted in lesion scores between treatment groups.
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Experiment 1 Naive 5 0.5 (0-1) 0(0-1)
Immune 5 1.5 (0-3) 0(0-1)
Immune/control 5 0.5(0-3) 1 (0-2 .5)
Experiment 2 Naive 5 0(0-1) 0(0-0.5)
Immune 4 1 .25(0-2) 0.75 (0-2)
Immune/control 3 0(0-2.5) 0
Infusion ofRMCP-II No albumin 4 1 (0--2) 0
Albumin 6 1 (0-3) 0(0-3)Figure 10 .
￿
Light micrographs of sections ofjejunum taken after ex vivo perfusion, stained with hematoxylin and eosin. Sections from naive rat je-
junum (A) after challenge with N . brasiliensis worm antigen and (B) after infusion o£the maximum dose ofRMCP-II . Note the absence ofgross morpho-
logical changes after perfusion . (X 350 .)
appearance of the protease in the lumen of the jejunum 2-6
min later . Importantly, the translocation of EB-HSA was
significantly correlated with the concentration of RMCP-
II in the gut lumen, over the period of infusion (Fig . 9) .
These results were again supported by SDS-PAGE show-
ing increased amounts ofEB-HSA correlating with the ap-
pearance ofRMCP-II in the gel and on the Western blot .
Thus, in both active anaphylaxis and in passive infusion of
RMCP-II, the development of mucosal permeability to
EB-HSA was invariably associated with the concomitant
appearance ofRMCP-II in the gut lumen .
These findings again suggest that RMCP-II could have a
direct role in causing epithelial permeability . However, the
relationship may not be a simple one . Two aspects will re-
quire further investigation : (i) what part, if any, does RMCP-
II have in promoting endothelial permeability? and (it)
could native inhibitors ofRMCP-II be active in the inter-
stitium of the lamina propria? The extent to which the lu-
minal surface of the endothelium might be a substrate for
RMCP-II when it has been infused intravascularly is not
known . Furthermore, variable hemodynamics in individual
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ex vivo perfusions could affect the rates at which the in-
fused RMCP-II reaches the mucosal interstitium . The rela-
tionship between the amount of RMCP-11 infused and
mucosal permeability could, similarly, be complicated by
the presence of inhibitors . Two distinct a l-protease inhibi-
tors (a t -PI) have been identified in rat plasma with an as-
sociation rate constant (Kris) for RMCP-II of 1-2 X 10 5
M-1 s-t (31) and there are preliminary data to suggest that
other a l-PI-like serpins are present in the gut mucosa (32) .
It may be significant, therefore, that the earliest detection
ofRMCP-II immunoreactivity in the gut lumen, after in-
fusion, is a high mol wt (70-kD) species possibly com-
plexed to a 1-PI (Fig . 8 B) . The presence of a second,
weakly labeled band of slightly lower mol wt (59 kD) at
later times presumably reflects the degradation of the com-
plex by free RMCP-II (Fig. 8 B) .
In vivo, RMCP-II released locally should, theoretically,
be inactivated by plasma-derived serpins flooding through
the endothelial gaps opened by histamine and other inflam-
matory mediators . However, our preliminary attempts to
mimic the in vivo role of serpins by infusing either nativeor synthetic inhibitors ex vivo were not successful because
of the very high concentrations that were required (data
not shown). When these same inhibitors were tested (at in-
hibitor/enzyme ratios of up to 10:1) against purified RMCP-
II at the molarities used in the ex vivo infusions, a residual
enzyme activity was consistently observed. It was not,
therefore, possible to use inhibitors to investigate the pro-
teolytic activity of RMCP-11 in the ex vivo perfusion
model. Nor is it likely that native inhibitors (the concentra-
tion of x1-PI in plasma is ^"3 mg/ml) are sufficiently abun-
dant to nullify the activity of the abundant RMCP-11 (4-6
mg/g wet wt of mucosa) released into the mucosa during
systemic anaphylaxis in vivo (32).
Absence of significant histological change, despite sub-
stantial leak of EB-HSA, was a consistent feature in this
study. Others have also noted increased mucosal perme-
ability in the absence of detectable lesions during immedi-
ate hypersensitivity reactions, even when ultrastructural
analysis was carried out (33) . There are, however, several
reports suggesting that mast cell activation is associated with
the separation of epithelium from basal lamina (4). A few
lesions of this type were noted in both control and experi-
mental rats but were not specifically related to permeability
changes nor to the release of RMCP-11. One of the pro-
posed targets for RMCP-11 is the epithelial basement mem-
brane (20) but, with laminin or type IV collagen as poten-
tial targets, proteolysis would probably take several hours





activated by RMCP-I1 (35), than by the direct action of
RMCP-11 itself. It is interesting to note, therefore, that ul-
trastructural lesions of the basement membrane associated
with IgE-mediated secretion of RMCP-11, were observed
4 h after challenge (4).
The very rapid development of macromolecular leak,
within 5 min ofchallenge or of infusion of RMCP-II, sug-
gests that proteolysis is directed against an immediately
accessible substrate. Therefore, the most likely target is a
paracellular, junctional complex protein which normally
maintains functional epithelial integrity. One possible tar-
get could be the rat equivalent of the recently described
chicken zonula occludens protein, occludin, which, from
its predicted amino acid sequence, has several chymo-
trypsin-sensitive sites in its extracellular domains (36). In
vitro studies using a pulmonary epithelial cell line have al-
ready shown that nanomolar concentrations of RMCP-II
can promote rapid and reversible permeability to macro-
molecules (37) by a mechanism independent of active ion
secretion (2). Similarly, a bacterial serine protease has re-
cently been shown to cause paracellular permeability in a
cultured epithelial cell line in association with loss of ex-
pression of the tightjunction protein, ZO-1 (38) . There is,
therefore, the intriguing possibility that the mucosal mast
cell chymases have a restricted substrate specificity so that,
when released, they can alter the permeability of the mu-
cosa, but not its structural integrity.
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